Heron Therapeutics (HRTX) Current Assets (2010 - 2026)

Heron Therapeutics (HRTX) has reported Current Assets for 17 consecutive years, with $229.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Assets rose 8.97% year-over-year to $229.8 million; the trailing twelve-month figure through Jun 2026 stood at $229.8 million (up 8.97% YoY), and the FY2025 full-year result was $238.1 million, up 13.9% from the prior year.
• Current Assets held at $229.8 million in Q2 2026 per HRTX's latest filing, from $229.0 million in the prior quarter.
• Across five years, Current Assets topped out at $238.1 million in Q4 2025 and bottomed at $165.3 million in Q2 2023.
• Historically, Current Assets has averaged $205.8 million across 5 years, with a median of $207.2 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Current Assets sank 47.06% in 2022, then advanced 17.53% in 2025.
• Over 5 years, Current Assets stood at $205.4 million in 2022, then fell by 8.11% to $188.8 million in 2023, then grew by 10.72% to $209.0 million in 2024, then rose by 13.9% to $238.1 million in 2025, then declined by 3.45% to $229.8 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $229.8 million, $229.0 million, and $238.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.